167 related articles for article (PubMed ID: 38201546)
1. CEP-1347 Dually Targets MDM4 and PKC to Activate p53 and Inhibit the Growth of Uveal Melanoma Cells.
Togashi K; Suzuki S; Mitobe Y; Nakagawa-Saito Y; Sugai A; Takenouchi S; Sugimoto M; Kitanaka C; Okada M
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201546
[TBL] [Abstract][Full Text] [Related]
2. CEP-1347 Targets MDM4 Protein Expression to Activate p53 and Inhibit the Growth of Glioma Cells.
Mitobe Y; Nakagawa-Saito Y; Togashi K; Suzuki S; Sugai A; Matsuda KI; Sonoda Y; Kitanaka C; Okada M
Anticancer Res; 2022 Oct; 42(10):4727-4733. PubMed ID: 36192008
[TBL] [Abstract][Full Text] [Related]
3. Antagonizing MDM2 Overexpression Induced by MDM4 Inhibitor CEP-1347 Effectively Reactivates Wild-Type p53 in Malignant Brain Tumor Cells.
Mitobe Y; Suzuki S; Nakagawa-Saito Y; Togashi K; Sugai A; Sonoda Y; Kitanaka C; Okada M
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686602
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
5. The Novel MDM4 Inhibitor CEP-1347 Activates the p53 Pathway and Blocks Malignant Meningioma Growth In Vitro and In Vivo.
Mitobe Y; Suzuki S; Nakagawa-Saito Y; Togashi K; Sugai A; Sonoda Y; Kitanaka C; Okada M
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509605
[TBL] [Abstract][Full Text] [Related]
6. Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.
Heijkants RC; Nieveen M; Hart KC'; Teunisse AFAS; Jochemsen AG
Oncogenesis; 2018 Mar; 7(3):33. PubMed ID: 29593251
[TBL] [Abstract][Full Text] [Related]
7. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.
Park JJ; Stewart A; Irvine M; Pedersen B; Ming Z; Carlino MS; Diefenbach RJ; Rizos H
Cancer Gene Ther; 2022 Oct; 29(10):1384-1393. PubMed ID: 35352024
[TBL] [Abstract][Full Text] [Related]
8. FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma.
Tarin M; Némati F; Decaudin D; Canbezdi C; Marande B; Silva L; Derrien H; Jochemsen AG; Gardrat S; Piperno-Neumann S; Rodrigues M; Mariani P; Cassoux N; Stern MH; Roman-Roman S; Alsafadi S
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190207
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of microRNA-130a represses uveal melanoma cell migration and invasion through inactivation of the Wnt/β-catenin signaling pathway by downregulating USP6.
Wu S; Han M; Zhang C
Cancer Gene Ther; 2022 Jul; 29(7):930-939. PubMed ID: 34522027
[TBL] [Abstract][Full Text] [Related]
10. CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells.
Štětková M; Growková K; Fojtík P; Valčíková B; Palušová V; Verlande A; Jorda R; Kryštof V; Hejret V; Alexiou P; Rotrekl V; Uldrijan S
Cell Death Dis; 2020 Sep; 11(9):754. PubMed ID: 32934219
[TBL] [Abstract][Full Text] [Related]
11. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
[TBL] [Abstract][Full Text] [Related]
12. PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma.
Park JJ; Hamad SA; Stewart A; Carlino MS; Lim SY; Rizos H
Oncogenesis; 2024 Feb; 13(1):9. PubMed ID: 38418838
[TBL] [Abstract][Full Text] [Related]
13. The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma.
Shu W; Zhu X; Wang K; Cherepanoff S; Conway RM; Madigan MC; Zhu H; Zhu L; Murray M; Zhou F
Cell Oncol (Dordr); 2022 Aug; 45(4):601-619. PubMed ID: 35781872
[TBL] [Abstract][Full Text] [Related]
14. MDM4 is a key therapeutic target in cutaneous melanoma.
Gembarska A; Luciani F; Fedele C; Russell EA; Dewaele M; Villar S; Zwolinska A; Haupt S; de Lange J; Yip D; Goydos J; Haigh JJ; Haupt Y; Larue L; Jochemsen A; Shi H; Moriceau G; Lo RS; Ghanem G; Shackleton M; Bernal F; Marine JC
Nat Med; 2012 Aug; 18(8):1239-47. PubMed ID: 22820643
[TBL] [Abstract][Full Text] [Related]
15. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
16. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
17. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
[TBL] [Abstract][Full Text] [Related]
18. MDM4 is a rational target for treating breast cancers with mutant p53.
Miranda PJ; Buckley D; Raghu D; Pang JB; Takano EA; Vijayakumaran R; Teunisse AF; Posner A; Procter T; Herold MJ; Gamell C; Marine JC; Fox SB; Jochemsen A; Haupt S; Haupt Y
J Pathol; 2017 Apr; 241(5):661-670. PubMed ID: 28097652
[TBL] [Abstract][Full Text] [Related]
19. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours.
Johansson PA; Brooks K; Newell F; Palmer JM; Wilmott JS; Pritchard AL; Broit N; Wood S; Carlino MS; Leonard C; Koufariotis LT; Nathan V; Beasley AB; Howlie M; Dawson R; Rizos H; Schmidt CW; Long GV; Hamilton H; Kiilgaard JF; Isaacs T; Gray ES; Rolfe OJ; Park JJ; Stark A; Mann GJ; Scolyer RA; Pearson JV; van Baren N; Waddell N; Wadt KW; McGrath LA; Warrier SK; Glasson W; Hayward NK
Nat Commun; 2020 May; 11(1):2408. PubMed ID: 32415113
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-145 suppresses uveal melanoma angiogenesis and growth by targeting neuroblastoma RAS viral oncogene homolog and vascular endothelial growth factor.
Yang JY; Li Y; Wang Q; Zhou WJ; Yan YN; Wei WB
Chin Med J (Engl); 2020 Aug; 133(16):1922-1929. PubMed ID: 32826455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
